Title: Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Journal: Journal of medicinal chemistry 20131024
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110515
Title: FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Journal: Blood 20110324
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: [FLT3 kinase inhibitors for the treatment of acute leukemia].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20100601
Title: FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Journal: Blood 20100218
Title: KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.
Journal: Blood 20090820
Title: Shiotsu Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
1005036-73-6 | 3H-Cyclopenta[c]quinoline, 6,8-difluoro-3a,4,5,9b-tetrahydro-4-(3-pyridinyl)- | AA00023X | MFCD04128902